Giving enough of the functional protein, usually recombinant (laboratory manufactured), which is missing or faulty in people with EB. This could be given via local injections, via microneedles and work is ongoing to deliver systemically by an intravenous route.
Researchers Dr’s Woodley and Chen of the University of Southern California (USC) are pioneering protein replacement therapy for Dystrophic EB. This technology was purchased by Shire Pharmaceutical, but the work is currently on hold. It has recently been adopted by Phoenix Tissue Repair – we await further progress
Protein replacement therapy would not cure EB but has potential to be a “quality of life changing”-treatment. Future research in this area could include investigating topical and ocular applications.